Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
Date:5/26/2010

the clinical benefit rate (complete response (CR) + partial response (PR) + stable disease (SD)) of intravenous multiple doses of REOLYSIN in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer. The secondary objectives are to determine the progression-free survival, and to determine the safety and tolerability of REOLYSIN when administered in combination with gemcitabine.

This trial is part of a broad preclinical and clinical collaboration with the CTRC that will involve up to five, open-label, Phase 2 studies exploring the use of REOLYSIN in combination with chemotherapy for various cancer indications.

About Pancreatic Cancer

The American Cancer Society estimates that 42,470 Americans were diagnosed with pancreatic cancer and 35,420 Americans died from the disease in 2009, making this type of cancer the fourth leading cause of cancer death in the United States.

For more information about pancreatic cancer, please go to www.cancer.org.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN(R), its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit:

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
(Date:7/10/2014)... the fight against terrorism with the creation of a ... the use of light and special glass fibres. , ... Chemical , the researchers describe a novel optical fibre ... as 6.3 ppm (parts per million). It requires an ... explosives detection has involved looking for metals that encase ...
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2
... Immucor, Inc. (Nasdaq:,BLUD), a global leader in providing automated instrument-reagent ... the fiscal year ending May 31, 2009., For fiscal ... $292 million to $300 million., -- ... to 71%., -- Net income is expected to be in ...
... DANBURY, Conn., June 4 Biodel Inc. (Nasdaq:,BIOD) today ... Corporate Development and Treasurer of Biodel, will present a,corporate ... on,Friday, June 6, 2008 at 1:40 p.m. Pacific Daylight ... San Francisco., Interested parties may access a link ...
... held in ... Georgia, ATLANTA, June 4 ... 17 -- 20, in,San Diego, Calif. Governor Perdue will deliver remarks on June ... of the fastest-growing industries in the nation, the,biosciences sector is a strategic priority ...
Cached Biology Technology:Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance 2Immucor Announces Fiscal Year 2009 Revenue and Earnings Guidance 3Georgia Showcases its Bioscience Leadership at 2008 Bio International Convention 2Georgia Showcases its Bioscience Leadership at 2008 Bio International Convention 3
(Date:7/10/2014)... open ocean as a microbial megacity, teeming with life ... water, hundreds of types of bacteria can be found. ... ocean microbes have their own daily cyclesnot unlike the ... up, commute, work, and eat at the same times., ... photoautotrophsbacteria that need solar energy to help them photosynthesize ...
(Date:7/10/2014)... if you are a big, bad sea scorpion. , ... waters for any prey in sight. The next, thanks ... you,re reduced to trolling for weaker, soft-bodied animals you ... of the giant pterygotid eurypterid, the largest arthropod that ... in the journal Biology Letters , dramatically re-interprets ...
(Date:7/10/2014)... JUPITER, FL, July 10, 2014 Amidst the astounding ... of synaptic connections in the brain, how do nerve ... connections to build? How do they coordinate these events ... scientists from the Florida campus of The Scripps Research ... processes, showing that a particular protein plays a far ...
Breaking Biology News(10 mins):New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3Extinct sea scorpion gets a Yale eye exam, with surprising results 2Scripps Florida scientists shed new light on nerve cell growth 2
... FAHA, the Aram V. Chobanian Professor of Cardiovascular ... at Boston University School of Medicine (BUSM), has ... Distinguished Scientist. The AHA designated only five Distinguished ... Distinguished Scientist designation in 2003 to recognize science ...
... at Boston University School of Medicine (BUSM) have brought attention ... and their infants from consuming brown seaweed soup. Seaweed is ... there is no scientific data on the iodine content in ... Editor for the journal Thyroid and published online, ...
... What looks like a spongy ball wrapped in strands ... be key to unlocking better methods for catalysis, artificial ... University chemists who have created a platform to analyze ... photoluminescent materials. The microscopic particles assembled in ...
Cached Biology News:BUSM professor selected as American Heart Association Distinguished Scientist 2BUSM researchers urge awareness of dietary iodine intake in postpartum Korean-American women 2Supramolecules get time to shine 2Supramolecules get time to shine 3
... Salmonella genomes has allowed the development of ... pairs. The S. enterica Typhimurium (strain LT2) ... bp; 4,440 ORFs) and a plasmid, pSLT ... Sigma-Genosys have been designed to amplify all ...
... The Bio-Stack Twister II Microplate ... top automation solution for integrating BioTeks ... together with expandable microplate capacity, ultimate ... Whether you are adding capacity to ...
XPLAC (S-17)...
Request Info...
Biology Products: